Serina Therapeutics, Inc. Interest Expense
Serina Therapeutics, Inc. (SER) reported Interest Expense of $99.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-14
- Serina Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $99.00K, a 15.12% increase year-over-year.
- Serina Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was -$28.00K, a 102.86% decline year-over-year.
- Serina Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $3.04M, a 228.93% increase year-over-year.
- Serina Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $792.00K, a 8.23% decline year-over-year.
- Serina Therapeutics, Inc. interest expense for fiscal 2023 was $4.90M, a 46.93% increase from fiscal 2022.
- Serina Therapeutics, Inc. interest expense for fiscal 2022 was $3.33M, a 204.01% increase from fiscal 2021.
- Serina Therapeutics, Inc. interest expense for fiscal 2021 was $1.10M.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $99.00K 10-Q · filed 2024-05-14 | $71.00K derived: sum of 2 quarters · filed 2024-05-14 | $3.11M derived: sum of 3 quarters · filed 2024-05-14 | $3.90M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $3.01M derived: sum of 2 quarters · filed 2024-03-22 | $3.80M derived: sum of 3 quarters · filed 2024-03-22 | $4.90M 10-K · filed 2024-03-22 | |
| 2023-09-30 | $3.04M 10-Q · filed 2023-11-14 | $3.83M derived: sum of 2 quarters · filed 2023-11-14 | $4.93M 10-Q · filed 2023-11-14 | $4.89M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-06-30 | $792.00K 10-Q · filed 2023-08-14 | $1.89M 10-Q · filed 2023-08-14 | $1.86M derived: sum of 3 quarters · filed 2024-05-14 | $2.78M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-03-31 | $86.00K 10-Q · filed 2024-05-14 | $1.10M 10-Q · filed 2023-05-12 | $1.06M derived: sum of 2 quarters · filed 2024-05-14 | $1.99M derived: sum of 3 quarters · filed 2024-05-14 | $2.85M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $978.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $1.90M derived: sum of 2 quarters · filed 2024-03-22 | $2.76M derived: sum of 3 quarters · filed 2024-03-22 | $3.33M 10-K · filed 2024-03-22 | |
| 2022-09-30 | $923.00K 10-Q · filed 2023-11-14 | $1.79M derived: sum of 2 quarters · filed 2023-11-14 | $2.36M 10-Q · filed 2023-11-14 | $2.65M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $863.00K 10-Q · filed 2023-08-14 | $1.43M 10-Q · filed 2023-08-14 | $1.73M derived: sum of 3 quarters · filed 2023-08-14 | $2.01M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $571.00K 10-Q · filed 2023-05-12 | $866.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.15M derived: sum of 3 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $580.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.10M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $285.00K 10-Q · filed 2022-11-10 | $802.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |